Instrument Inactif

Autres langues InterCure Ltd. TEL AVIV STOCK EXCHANGE

Actions

INCR

IL0011063760

Installations et services en soins de santé

Autres langues

08/09	InterCure Regains Nasdaq Compliance
08/09	InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
25/08	InterCure Ltd. announced that it has received ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors.
24/08	Intercure Ltd. Finalizes Settlement for War-Related Indirect Damages with the Israeli Tax Authorities and Compensation Fund the Subsequent War
24/08	InterCure Finalizes NIS 230 Million (~US$77 Million) Settlement for War-Related Indirect Damages
19/08	InterCure Ltd. Announces 1-for-5 Reverse Share Split
22/06	InterCure Ltd. announced that it expects to receive ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors.
22/06	InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds
15/06	InterCure Starts Review of US Medical Cannabis Opportunities; Completes Initial Closing of Botanico Acquisition
15/06	InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition
15/06	InterCure Ltd. acquired 50% stake of Botanico Ltd.
15/06	InterCure Ltd. completed the acquisition of 50% stake in Botanico Ltd.
01/05	InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow
30/04	InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025
03/03	InterCure Receives Noncompliance Notice From Nasdaq
03/03	InterCure receives Nasdaq notification regarding minimum bid requirement
03/03	InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement
19/02	InterCure announces preliminary estimated 2025 revenue of NIS 265 million, positive adjusted EBITDA and cash of NIS 43 million
19/02	InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million
19/12	InterCure Ltd on Dec 15, became aware that Bazelet Group of Companies has initiated Restructuring proceedings before the Israeli district court
03/11	Cannasoul Analytics Ltd. announced that it expects to receive funding from InterCure Ltd.
03/11	InterCure Ltd. Enters into A Collaboration Agreement with Cannasoul R&D Ltd
03/11	InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation
08/10/25	InterCure Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025
08/10/25	Intercure reports first half 2025 results with NIS 130 million in revenue and positive operating cash flow